Help appealing denials for this first oral treatment for acromegaly.

Appeal Your Palsonify Denial

Get access to the first once-daily oral treatment for acromegaly.

Start Your Appeal
Chat with AI Assistant

Understanding Your Palsonify (paltusotine) Denial

Palsonify (paltusotine) is the first and only once-daily oral medication approved for acromegaly in adults who have had inadequate response to surgery or for whom surgery is not an option. This represents a major advance over injectable somatostatin analogs. Insurance denials often require documentation of surgery failure or ineligibility.

Common Reasons for Denial

  • ! Prior authorization required
  • ! Must try injectable somatostatin analogs first
  • ! Surgical history not documented
  • ! IGF-1 levels not provided
  • ! Specialty tier drug not covered
  • ! New drug with limited coverage policies

How We Help

We help you document your acromegaly diagnosis, surgical history, IGF-1 levels, prior treatment with injectables, and why oral therapy is medically necessary for you.

Start your Palsonify appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Paltusotine is an oral somatostatin receptor agonist that suppresses growth hormone secretion in acromegaly.

✓ Clinical trials demonstrated effective control of IGF-1 levels with once-daily oral dosing.

✓ Oral therapy eliminates the burden of monthly injections, improving quality of life and treatment adherence.

✓ Acromegaly causes serious complications including cardiovascular disease, diabetes, and joint problems if not adequately controlled.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

CrinetiCARE Patient Support ↗

Eligible commercially insured patients may pay as little as $0. Bridge program available while awaiting coverage. Patient assistance for uninsured/underinsured patients. Visit CrinetiCARE.com or Palsonify.com.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

National Organization for Rare Disorders (NORD) ↗

Leading patient advocacy organization for rare disease community.

Global Genes ↗

Leading rare disease patient advocacy organization connecting and empowering patients.

Frequently Asked Questions

You need to have either had inadequate response to pituitary surgery or have a reason why surgery is not an option for you (tumor location, surgical risk, patient preference with documented discussion). Your endocrinologist should document this.

Document why you want to switch to oral therapy, including injection-site reactions, needle phobia, inconvenience of monthly injections, or need for more flexible dosing. Some insurers may require documented inadequate response to injectables.

Include your IGF-1 levels before and during treatment, showing they are above normal range (indicating active acromegaly) or documenting your response to current therapy.

Ready to Fight Your Palsonify (paltusotine) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Crinetics Pharmaceuticals. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.